Voskuil, F. J. http://orcid.org/0000-0003-3740-4554
Steinkamp, P. J. http://orcid.org/0000-0003-4228-063X
Zhao, T.
van der Vegt, B. http://orcid.org/0000-0002-2613-1506
Koller, M.
Doff, J. J.
Jayalakshmi, Y.
Hartung, J. P.
Gao, J. http://orcid.org/0000-0003-0726-5098
Sumer, B. D. http://orcid.org/0000-0002-8371-4388
Witjes, M. J. H.
van Dam, G. M. http://orcid.org/0000-0002-7248-8696
Albaroodi, Y.
Been, L. B.
Dijkstra, F.
van Etten, B.
Feng, Q.
van Ginkel, R. J.
Hall, K.
Havenga, K.
Haveman, J. W.
Hemmer, P. H. J.
Jansen, L.
de Jongh, S. J.
Kats-Ugurlu, G.
Kelder, W.
Kruijff, S.
Kruithof, I.
van Loo, E.
Roodenburg, J. L. N.
Shenoy, N.
Schepman, K. P.
de Visscher, S. A. H. J.
,
Article History
Received: 4 February 2020
Accepted: 27 May 2020
First Online: 26 June 2020
Competing interests
: B.D.S. and J.G. are advisors, Y.J., T.Z., and Y.A. are employees and N.S. is a consultant at OncoNano Medicine Inc. B.D.S., J.G., Y.J., T.Z., Y.A., and N.S. are shareholders of OncoNano Medicine Inc. J.P.H. is an owner of JPH Clinical Development Inc and is a consultant at OncoNano Medicine Inc. The research was funded by OncoNano Medicine Inc. G.M.v.D. is a member of the Scientific Advisory Board of SurgVision BV as well as the CEO, founder, and shareholder of AxelaRx/TRACER BV. The sponsor (OncoNano Medicine Inc.) participated in the study design, the data were analyzed independently of the sponsor. The sponsor delivered technical advice for writing the paper (B.D.S. and J.G.). All other authors declare no competing interests.